NCT06772740 Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma
| NCT ID | NCT06772740 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kazutaka Uchida |
| Condition | Endovascular Treatment |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-12-23 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2024-12-23 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.
Eligibility Criteria
Inclusion Criteria: 1. Age \>=18 2. pre-mRS 0-3 3. Hematoma thickness \>=10mm 4. Having at least one risk factor Risk factor: Age \>=75, Antithrombotic therapy, DM, Bilateral hematoma, Markwalder grading score \>3, Preoperative volume \>=130ml, Preoperative midline shift \>=8mm, CT appearance (Homogeneous, laminar or separated) Exclusion Criteria: 1. Cr \>=1.8 2. Plt \<50,000, PT-INR \>2 3. Life expectancy \<6 months
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06772740 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Endovascular Treatment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06772740 currently recruiting?
Yes, NCT06772740 is actively recruiting participants. Contact the research team at fu-sakakibara@hyo-med.ac.jp for enrollment information.
Where is the NCT06772740 trial being conducted?
This trial is being conducted at Nishinomiya, Japan.
Who is sponsoring the NCT06772740 clinical trial?
NCT06772740 is sponsored by Kazutaka Uchida. The trial plans to enroll 600 participants.